BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 25, 2007
View Archived Issues
PTC Therapeutics reports phase II trial data of PTC-124 for Duchenne muscular dystrophy
Read More
GenVec receives additional funding to develop novel adenovector-based HIV vaccines
Read More
Nventa reports update on phase I trial of new HspE-7 for cervical dysplasia
Read More
Two phase III studies show efficacy of asenapine in treating mania in bipolar I disorder
Read More
Preliminary PROTECT-1 results show efficacy of CCX-282-B in Crohn's disease
Read More
Barrier announces positive results from phase IIa study of pramiconazole in onychomycosis
Read More
Recent patents cover novel discoveries for the treatment of cancer
Read More
Approval obtained in Japan for additional pediatric indications for Claritin
Read More
Positive one-year results reported for fully bioabsorbable drug-eluting stent
Read More
New therapeutic agents for metabolic disorders reported in recent patents
Read More
EMEA supports use of rosiglitazone for type 2 diabetes
Read More
Recent Johns Hopkins patent imparts new nitroxyl (HNO) donors for cardiovascular disorders
Read More
Clinical trials add to evidence of adalimumab efficacy in Crohn's disease
Read More
Biogen Idec agents discussed at multiple sclerosis congress
Read More
Positive results reported for phase I FT-105 basal insulin trial
Read More
Tezampanel meets primary endpoint in phase IIb migraine trial
Read More
Xience V everolimus-eluting stent shows continued superiority to Taxus
Read More
Peregrine submits clinical protocol for new phase II bavituximab trial
Read More
Speedel discontinues SPP-200 development and focuses on SPP-301 and next-generation renin inhibitors
Read More
Tyrosinase DNA vaccines induce T-cell responses in melanoma patients
Read More
Genzyme acquires Bioenvision and gains rights to clofarabine
Read More
Orexigen's Contrave begins third phase III trial for treatment of obesity
Read More
Genzyme's Elaprase IV 6 mg launched in Japan
Read More
CHMP issues positive opinion of MabCampath in B-CLL therapy
Read More
Genzyme's Cholestagel launched in Europe
Read More
Noven receives FDA approvable letter for Stavzor
Read More